APO RESEARCH · REPORT
Hemocompatible Coatings
Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.
Product & engineering
Understand the product.
Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.
Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.
Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.
Selected research
Industry Research
Hemocompatible Coatings Industry Research Report 2026
Market perspective
Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.
Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.
Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.
Read the full market overview
The global Hemocompatible Coatings market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hemocompatible Coatings market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hemocompatible Coatings market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hemocompatible Coatings market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hemocompatible Coatings include Surmodics, Carmeda AB, Coatings2Go, DSM Biomedical, Hydromer, AST Products, Smart Reactors, Alfa Chemistry and Biomerics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hemocompatible Coatings market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hemocompatible Coatings.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hemocompatible Coatings Market by Company
Surmodics
Carmeda AB
Coatings2Go
DSM Biomedical
Hydromer
AST Products
Smart Reactors
Alfa Chemistry
Biomerics
Jiangsu Biosurf Biotech
Corline Biomedical
BioInteractions
Aurorium
Alta Biomed
jMedtech
Hemocompatible Coatings Segment by Type
Active (heparin)
Passive (non-heparin)
Hemocompatible Coatings Segment by Application
Interventional Catheters
ECMO & Extracorporeal
Stents & Vascular Grafts
Hemocompatible Coatings Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemocompatible Coatings market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemocompatible Coatings and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemocompatible Coatings.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hemocompatible Coatings companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Active (heparin)
- Passive (non-heparin)
Applications
- Interventional Catheters
- ECMO & Extracorporeal
- Stents & Vascular Grafts
Companies covered
- Surmodics
- Carmeda AB
- Coatings2Go
- DSM Biomedical
- Hydromer
- AST Products
- Smart Reactors
- Alfa Chemistry
- Biomerics
- Jiangsu Biosurf Biotech
- Corline Biomedical
- BioInteractions
- Aurorium
- Alta Biomed
- jMedtech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hemocompatible Coatings by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Active (heparin)
- 2.2.3 Passive (non-heparin)
- 2.3 Hemocompatible Coatings by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Interventional Catheters
- 2.3.3 ECMO & Extracorporeal
- 2.3.4 Stents & Vascular Grafts
- 2.4 Assumptions and Limitations
3 Hemocompatible Coatings Breakdown Data by Type
- 3.1 Global Hemocompatible Coatings Historic Market Size by Type (2021-2026)
- 3.2 Global Hemocompatible Coatings Forecasted Market Size by Type (2027-2032)
4 Hemocompatible Coatings Breakdown Data by Application
- 4.1 Global Hemocompatible Coatings Historic Market Size by Application (2021-2026)
- 4.2 Global Hemocompatible Coatings Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hemocompatible Coatings Market Perspective (2021-2032)
- 5.2 Global Hemocompatible Coatings Growth Trends by Region
- 5.2.1 Global Hemocompatible Coatings Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hemocompatible Coatings Historic Market Size by Region (2021-2026)
- 5.2.3 Hemocompatible Coatings Forecasted Market Size by Region (2027-2032)
- 5.3 Hemocompatible Coatings Market Dynamics
- 5.3.1 Hemocompatible Coatings Industry Trends
- 5.3.2 Hemocompatible Coatings Market Drivers
- 5.3.3 Hemocompatible Coatings Market Challenges
- 5.3.4 Hemocompatible Coatings Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hemocompatible Coatings Players by Revenue
- 6.1.1 Global Top Hemocompatible Coatings Players by Revenue (2021-2026)
- 6.1.2 Global Hemocompatible Coatings Revenue Market Share by Players (2021-2026)
- 6.2 Global Hemocompatible Coatings Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hemocompatible Coatings Head Office and Area Served
- 6.4 Global Hemocompatible Coatings Players, Product Type & Application
- 6.5 Global Hemocompatible Coatings Manufacturers Established Date
- 6.6 Global Hemocompatible Coatings Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hemocompatible Coatings Market Size (2021-2032)
- 7.2 North America Hemocompatible Coatings Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hemocompatible Coatings Market Size by Country (2021-2026)
- 7.4 North America Hemocompatible Coatings Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hemocompatible Coatings Market Size (2021-2032)
- 8.2 Europe Hemocompatible Coatings Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hemocompatible Coatings Market Size by Country (2021-2026)
- 8.4 Europe Hemocompatible Coatings Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hemocompatible Coatings Market Size (2021-2032)
- 9.2 Asia-Pacific Hemocompatible Coatings Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hemocompatible Coatings Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hemocompatible Coatings Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hemocompatible Coatings Market Size (2021-2032)
- 10.2 South America Hemocompatible Coatings Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hemocompatible Coatings Market Size by Country (2021-2026)
- 10.4 South America Hemocompatible Coatings Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hemocompatible Coatings Market Size (2021-2032)
- 11.2 Middle East & Africa Hemocompatible Coatings Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hemocompatible Coatings Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hemocompatible Coatings Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Surmodics
- 12.1.1 Surmodics Company Information
- 12.1.2 Surmodics Business Overview
- 12.1.3 Surmodics Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.1.4 Surmodics Hemocompatible Coatings Product Portfolio
- 12.1.5 Surmodics Recent Developments
- 12.2 Carmeda AB
- 12.2.1 Carmeda AB Company Information
- 12.2.2 Carmeda AB Business Overview
- 12.2.3 Carmeda AB Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.2.4 Carmeda AB Hemocompatible Coatings Product Portfolio
- 12.2.5 Carmeda AB Recent Developments
- 12.3 Coatings2Go
- 12.3.1 Coatings2Go Company Information
- 12.3.2 Coatings2Go Business Overview
- 12.3.3 Coatings2Go Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.3.4 Coatings2Go Hemocompatible Coatings Product Portfolio
- 12.3.5 Coatings2Go Recent Developments
- 12.4 DSM Biomedical
- 12.4.1 DSM Biomedical Company Information
- 12.4.2 DSM Biomedical Business Overview
- 12.4.3 DSM Biomedical Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.4.4 DSM Biomedical Hemocompatible Coatings Product Portfolio
- 12.4.5 DSM Biomedical Recent Developments
- 12.5 Hydromer
- 12.5.1 Hydromer Company Information
- 12.5.2 Hydromer Business Overview
- 12.5.3 Hydromer Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.5.4 Hydromer Hemocompatible Coatings Product Portfolio
- 12.5.5 Hydromer Recent Developments
- 12.6 AST Products
- 12.6.1 AST Products Company Information
- 12.6.2 AST Products Business Overview
- 12.6.3 AST Products Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.6.4 AST Products Hemocompatible Coatings Product Portfolio
- 12.6.5 AST Products Recent Developments
- 12.7 Smart Reactors
- 12.7.1 Smart Reactors Company Information
- 12.7.2 Smart Reactors Business Overview
- 12.7.3 Smart Reactors Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.7.4 Smart Reactors Hemocompatible Coatings Product Portfolio
- 12.7.5 Smart Reactors Recent Developments
- 12.8 Alfa Chemistry
- 12.8.1 Alfa Chemistry Company Information
- 12.8.2 Alfa Chemistry Business Overview
- 12.8.3 Alfa Chemistry Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.8.4 Alfa Chemistry Hemocompatible Coatings Product Portfolio
- 12.8.5 Alfa Chemistry Recent Developments
- 12.9 Biomerics
- 12.9.1 Biomerics Company Information
- 12.9.2 Biomerics Business Overview
- 12.9.3 Biomerics Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.9.4 Biomerics Hemocompatible Coatings Product Portfolio
- 12.9.5 Biomerics Recent Developments
- 12.10 Jiangsu Biosurf Biotech
- 12.10.1 Jiangsu Biosurf Biotech Company Information
- 12.10.2 Jiangsu Biosurf Biotech Business Overview
- 12.10.3 Jiangsu Biosurf Biotech Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.10.4 Jiangsu Biosurf Biotech Hemocompatible Coatings Product Portfolio
- 12.10.5 Jiangsu Biosurf Biotech Recent Developments
- 12.11 Corline Biomedical
- 12.11.1 Corline Biomedical Company Information
- 12.11.2 Corline Biomedical Business Overview
- 12.11.3 Corline Biomedical Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.11.4 Corline Biomedical Hemocompatible Coatings Product Portfolio
- 12.11.5 Corline Biomedical Recent Developments
- 12.12 BioInteractions
- 12.12.1 BioInteractions Company Information
- 12.12.2 BioInteractions Business Overview
- 12.12.3 BioInteractions Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.12.4 BioInteractions Hemocompatible Coatings Product Portfolio
- 12.12.5 BioInteractions Recent Developments
- 12.13 Aurorium
- 12.13.1 Aurorium Company Information
- 12.13.2 Aurorium Business Overview
- 12.13.3 Aurorium Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.13.4 Aurorium Hemocompatible Coatings Product Portfolio
- 12.13.5 Aurorium Recent Developments
- 12.14 Alta Biomed
- 12.14.1 Alta Biomed Company Information
- 12.14.2 Alta Biomed Business Overview
- 12.14.3 Alta Biomed Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.14.4 Alta Biomed Hemocompatible Coatings Product Portfolio
- 12.14.5 Alta Biomed Recent Developments
- 12.15 jMedtech
- 12.15.1 jMedtech Company Information
- 12.15.2 jMedtech Business Overview
- 12.15.3 jMedtech Revenue in Hemocompatible Coatings Business (2021-2026)
- 12.15.4 jMedtech Hemocompatible Coatings Product Portfolio
- 12.15.5 jMedtech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst